On January 12, 2026, PTC Therapeutics, Inc. announced preliminary financial results for 2025, expecting approximately $823.4 million in net product revenue and provided guidance of $700 million to $800 million for 2026. This filing is significant as it outlines expected revenues and financial guidance for the near future.